This new portal is an online, secure interactive system that allows interested individuals to submit nominations for membership to any of the agency’s many advisory committees.
On Wednesday, the U.S. Food and Drug Administration launched the advisory committee membership nomination portal, changing the way in which panelists are brought on to advisory committees and catching up with this technology-driven age.
This new portal is an online, secure interactive system that allows interested individuals to submit nominations for membership to any of the agency’s many advisory committees. It allows individuals to submit their application for an advisory committee membership from the FDA’s website, creating a paperless, streamlined process that will enable the agency to accept, evaluate, and ultimately nominate qualified individuals for membership in an efficient manner.
Check the new FDA portal out HERE
With respect to applicant evaluation, this streamlined system will essentially allow the FDA to develop metrics for assessing the entire applicant pool which will make identifying qualified candidates easier and thus, faster. Currently, applications must either be emailed or mailed to the agency which can be a long and tedious process.
“The portal allows applicants to complete their entire application online,” said Jill Hartzler Warner, J.D., acting associate commissioner of the FDA’s Office of Special Medical Programs. “Applicants will experience an interactive, step-by-step process that eliminates confusion and accelerates the timeframe for submitting and processing an application.”
Additionally, nominations for scientific members and consumer and industry representatives may be submitted by professional societies, industry and consumer groups, and other interested persons and organizations. Potential candidates are asked to provide detailed information regarding financial holdings, employment, and research grants and/or contracts in order to explore the possibility of an applicant having any conflicts of interest.
In an attempt to save time and energy, the FDA is also posting a set of presentation slides on conflicts of interest, which will allow applicants to answer preliminary questions and self-evaluate whether they may have conflicts of interest that will prevent them from being nominated to an advisory committee. View the conflicts of interest slides HERE!
Advisory committees provide the FDA with independent, expert advice on a range of complex scientific, technical, and policy issues. The FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups.
Find out more about current advisory committee vacancies and the qualifications and experience expected from nominees by clicking HERE.
For more information regarding applying for membership, click HERE.
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact email@example.com
Interested in learning about ISS’ expert approach to Advisory Committee Meetings? Click below in order to find out for yourself!
Subscribe to ISS’ blog to have access to advisory committee meeting updates, free giveaways and more!
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us